94.29 USD
-1.74 (-1.81%)
94.29 USD
0 (0%)
MIRM gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. While MIRM seems to be doing ok healthwise, there are quite some concerns on its profitability. MIRM is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
- MIRM had negative earnings in the past year.
- In the past year MIRM had a positive cash flow from operations.
- In the past 5 years MIRM always reported negative net income.
- In the past 5 years MIRM reported 4 times negative operating cash flow.
1.2 Ratios
- The Return On Assets of MIRM (-5.30%) is better than 86.10% of its industry peers.
- The Return On Equity of MIRM (-14.26%) is better than 86.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.3% | ||
| ROE | -14.26% | ||
| ROIC | N/A |
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 79.92%, MIRM belongs to the top of the industry, outperforming 85.14% of the companies in the same industry.
- MIRM's Gross Margin has declined in the last couple of years.
- MIRM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- MIRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, MIRM has more shares outstanding
- MIRM has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for MIRM has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 5.71 indicates that MIRM is not in any danger for bankruptcy at the moment.
- MIRM has a better Altman-Z score (5.71) than 74.10% of its industry peers.
- MIRM has a debt to FCF ratio of 6.97. This is a slightly negative value and a sign of low solvency as MIRM would need 6.97 years to pay back of all of its debts.
- MIRM has a Debt to FCF ratio of 6.97. This is amongst the best in the industry. MIRM outperforms 91.43% of its industry peers.
- A Debt/Equity ratio of 1.06 is on the high side and indicates that MIRM has dependencies on debt financing.
- Looking at the Debt to Equity ratio, with a value of 1.06, MIRM is doing worse than 75.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.06 | ||
| Debt/FCF | 6.97 | ||
| Altman-Z | 5.71 |
ROIC/WACCN/A
WACC8.61%
2.3 Liquidity
- A Current Ratio of 3.31 indicates that MIRM has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 3.31, MIRM is doing worse than 60.38% of the companies in the same industry.
- MIRM has a Quick Ratio of 3.16. This indicates that MIRM is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 3.16, MIRM is in line with its industry, outperforming 40.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.31 | ||
| Quick Ratio | 3.16 |
3. Growth
3.1 Past
- MIRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.43%, which is quite impressive.
- Looking at the last year, MIRM shows a very strong growth in Revenue. The Revenue has grown by 53.66%.
- The Revenue has been growing by 160.12% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)57.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
Revenue 1Y (TTM)53.66%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%47.17%
3.2 Future
- MIRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.81% yearly.
- MIRM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.75% yearly.
EPS Next Y82.41%
EPS Next 2Y36.19%
EPS Next 3Y30.14%
EPS Next 5Y30.81%
Revenue Next Year53.05%
Revenue Next 2Y36.61%
Revenue Next 3Y30.36%
Revenue Next 5Y26.75%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for MIRM. In the last year negative earnings were reported.
- Also next year MIRM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, MIRM is valued cheaply inside the industry as 91.24% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 109.12 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- MIRM's earnings are expected to grow with 30.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.19%
EPS Next 3Y30.14%
5. Dividend
5.1 Amount
- No dividends for MIRM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MIRUM PHARMACEUTICALS INC / MIRM FAQ
What is the fundamental rating for MIRM stock?
ChartMill assigns a fundamental rating of 4 / 10 to MIRM.
What is the valuation status for MIRM stock?
ChartMill assigns a valuation rating of 2 / 10 to MIRUM PHARMACEUTICALS INC (MIRM). This can be considered as Overvalued.
Can you provide the profitability details for MIRUM PHARMACEUTICALS INC?
MIRUM PHARMACEUTICALS INC (MIRM) has a profitability rating of 3 / 10.
Can you provide the expected EPS growth for MIRM stock?
The Earnings per Share (EPS) of MIRUM PHARMACEUTICALS INC (MIRM) is expected to grow by 82.41% in the next year.